Last reviewed · How we verify
Cilostazol group
Cilostazol group is a Phosphodiesterase-3 inhibitor Small molecule drug developed by Otsuka Beijing Research Institute. It is currently FDA-approved for Intermittent claudication due to peripheral arterial disease. Also known as: Pletaal.
Cilostazol inhibits phosphodiesterase-3 (PDE-3) to increase cAMP levels, promoting vasodilation and inhibiting platelet aggregation.
Cilostazol is a small molecule inhibitor of the cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A, classified as an INHIBITOR. It has been studied for various conditions, including intermittent claudication, peripheral arterial disease, and cerebral microbleeds, among others, with potential applications in treatments such as percutaneous coronary intervention.
At a glance
| Generic name | Cilostazol group |
|---|---|
| Also known as | Pletaal |
| Sponsor | Otsuka Beijing Research Institute |
| Drug class | Phosphodiesterase-3 inhibitor |
| Target | PDE-3 (Phosphodiesterase-3) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
By blocking PDE-3 in platelets and vascular smooth muscle cells, cilostazol elevates intracellular cAMP, which suppresses platelet activation and aggregation while promoting vasodilation. This dual antiplatelet and vasodilatory effect improves blood flow and reduces thrombotic events in peripheral arterial disease.
Approved indications
- Intermittent claudication due to peripheral arterial disease
Common side effects
- Headache
- Diarrhea
- Palpitations
- Dizziness
- Tachycardia
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Effect of Cilostazol in Promoting Hematoma Clearance After Intracerebral Hemorrhage (PHASE2)
- Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial (PHASE1)
- Cilostazol for Preventing Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage (PHASE3)
- Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease (PHASE1, PHASE2)
- Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol (PHASE4)
- Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cilostazol group CI brief — competitive landscape report
- Cilostazol group updates RSS · CI watch RSS
- Otsuka Beijing Research Institute portfolio CI
Frequently asked questions about Cilostazol group
What is Cilostazol group?
How does Cilostazol group work?
What is Cilostazol group used for?
Who makes Cilostazol group?
Is Cilostazol group also known as anything else?
What drug class is Cilostazol group in?
What development phase is Cilostazol group in?
What are the side effects of Cilostazol group?
What does Cilostazol group target?
Related
- Drug class: All Phosphodiesterase-3 inhibitor drugs
- Target: All drugs targeting PDE-3 (Phosphodiesterase-3)
- Manufacturer: Otsuka Beijing Research Institute — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Intermittent claudication due to peripheral arterial disease
- Also known as: Pletaal
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing